Literature DB >> 15351949

[Cardiovascular risk and renal transplantation].

G Stallone1, B Infante, A Schena, S Di Paolo, G Grandaliano, L Gesualdo, F P Schena.   

Abstract

Cardiovascular disease after renal transplantation is often the expression of a disease process that first started with the onset of renal dysfunction many years before, and its prevention starts with the early predialysis phase of chronic renal failure and with the aggressive treatment of hypertension and dyslipidemia. The evidence that dialysis treatment itself accelerates arterial damage is poor. After transplantation, however, many patients are restored to a state not of normal renal function but of chronic renal impairment and have drug-induced hypertension and dyslipidemia, resulting in a vastly increased risk of atherosclerosis. Further research is required on optimal strategies to prevent or ameliorate cardiovascular disease, to establish the roles of lipid-lowering and antihypertensive therapies after transplantation and to define immunosuppressive ad hoc treatments for each kind of patient.

Entities:  

Mesh:

Year:  2004        PMID: 15351949

Source DB:  PubMed          Journal:  G Ital Nefrol        ISSN: 0393-5590


  2 in total

1.  Nontoxic concentration of ochratoxin A decreases the dosage of cyclosporine A to induce chronic nephropathy model via autophagy mediated by toll-like receptor 4.

Authors:  Lili Hou; Guannan Le; Ziman Lin; Gang Qian; Fang Gan; Cong Gu; Shuai Jiang; Jiaxin Mu; Lei Ge; Kehe Huang
Journal:  Cell Death Dis       Date:  2020-02-27       Impact factor: 8.469

Review 2.  Use of antioxidants to prevent cyclosporine a toxicity.

Authors:  Jinhwa Lee
Journal:  Toxicol Res       Date:  2010-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.